1. Home
  2. INLF vs PMVP Comparison

INLF vs PMVP Comparison

Compare INLF & PMVP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

INLF

INLIF LIMITED

HOLD

Current Price

$3.19

Market Cap

70.7M

Sector

Industrials

ML Signal

HOLD

Logo PMV Pharmaceuticals Inc.

PMVP

PMV Pharmaceuticals Inc.

HOLD

Current Price

$1.43

Market Cap

76.8M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
INLF
PMVP
Founded
2016
2013
Country
China
United States
Employees
156
N/A
Industry
Industrial Machinery/Components
Medicinal Chemicals and Botanical Products
Sector
Industrials
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
70.7M
76.8M
IPO Year
N/A
2020

Fundamental Metrics

Financial Performance
Metric
INLF
PMVP
Price
$3.19
$1.43
Analyst Decision
Analyst Count
0
0
Target Price
N/A
N/A
AVG Volume (30 Days)
49.3K
436.3K
Earning Date
03-06-2026
05-08-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.24
$0.83
52 Week High
$5.20
$1.88

Technical Indicators

Market Signals
Indicator
INLF
PMVP
Relative Strength Index (RSI) 60.72 54.46
Support Level $0.40 $1.37
Resistance Level $5.20 $1.50
Average True Range (ATR) 0.20 0.07
MACD -0.13 0.01
Stochastic Oscillator 0.00 70.37

Price Performance

Historical Comparison
INLF
PMVP

About INLF INLIF LIMITED

INLIF Ltd, through its subsidiary, is engaged in the research, development, manufacturing, and sales of injection molding machine-dedicated manipulator arms. In addition, it offers installation and warranty services for manipulator arms, and accessories and raw materials for manipulator arms. Its portfolio includes injection molding machine-dedicated manipulator arms, including transverse single and double-axis manipulator arms, transverse and longitudinal multi-axis manipulator arms, and large bullhead multi-axis manipulator arms.

About PMVP PMV Pharmaceuticals Inc.

PMV Pharmaceuticals Inc is a precision oncology company. The company is engaged in the research and development of small molecule, tumor-agnostic therapies targeting p53 mutations, which can eliminate cancer cells. The key product candidate, rezatapopt, is designed to be an orally available small molecule that structurally corrects the mutant p53 protein with the Y220C mutation. Currently, the product candidates are undergoing preclinical and clinical testing, and company relies on third parties for the manufacture after marketing approvals.

Share on Social Networks: